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Lipophilic arabinofuranosyl cytosine derivatives in liposomes
Abstract
Highly lipophilic drugs can be used therapeutically only by the addition of possibly toxic solubilizing
agents or by development of complex pharmaceutical formulations. One way of overcoming these
disadvantages is the incorporation of such drugs into the bilayer matrix of phospholipid liposomes. To
this end, we chose the approach of chemical transformation of water-soluble nucleosides of known
cytotoxic properties into lipophilic drugs or prodrugs. Due to their insolubility, we developed
formulations that can be used for intravenous applications in which the lipophilic molecules are
incorporated into lipid bilayer membranes of small liposomes. We chose
1-beta-d-arabinofuranosylcytosine (ara-C) as a cytotoxic nucleoside, and we demonstrated that
N(4)-acyl derivatives of ara-C were active in vivo in various murine tumor models as liposomal
formulations. However, the protection against enzymatic deamination was only partially achieved and
was insufficient for significant improvement of cytotoxic properties. Thus, we synthesized a new class
of N(4)-alkyl-ara-C derivatives. The most effective derivative, N(4)-octadecyl-ara-C (NOAC), is highly
lipophilic and extremely resistant toward deamination. NOAC exerts excellent antitumor activity after
oral and parenteral therapy. The activity of NOAC against freshly explanted clonogenic cells from
human tumors was determined and compared with conventional antitumor agents. NOAC was used in
two liposomal preparations, a stable lyophilized and a freshly prepared liquid formulation. Both
formulations inhibited tumor colony formation equally in a concentration-dependent fashion. At optimal
conditions, liposomal NOAC had significantly better activity compared with the clinically used drugs
cisplatin, doxorubicin, 5-fluorouracil, gemcitabine, mitomycin C, and etoposide. Furthermore, in a
hematopoietic stem cell assay, NOAC was less toxic than ara-C and doxorubicin by factors ranging
from 2.5 to 200, indicating that this drug is well tolerated at high doses.
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Introduction 
 
In the field of drug delivery liposomes are predominantly used as carriers for hydrophilic 
molecules that are entrapped within their aqueous inner volume. Long circulating 
poly(ethylene glycol) modified liposomes with the cytotoxic drug doxorbicine are an 
example of such a clinically used formulation.1 Highly lipophilic drugs can only be used 
therapeutically by addition of possibly toxic solubilizing agents or by development of 
complex pharmaceutical formulations. One way of overcoming these disadvantages is 
the incorporation of such drugs into the bilayer matrix of phospholipid liposomes. 
We chose the approach of the chemical transformation of water-soluble nucleosides of 
known cytotoxic properties into lipophilic drugs or prodrugs. Due to the insolubility of 
these compounds we developed formulations that can be used for intravenous 
applications in which the lipophilic molecules are incorporated into lipid bilayer 
membranes of small unilamellar liposomes. Initially we chose 1-β-D-arabino-
furanosylcytosine (ara-C) as cytotoxic nucleoside because the major untoward 
properties of the drug are the short plasma half-life and rapid degradation by 
deamination to the inactive metabolite 1-β-D-arabinofuranosyluracil (ara-U), a 
disadvantage that also impedes the oral application of ara-C. 
To abolish these shortcomings a large number of 5'- and N
4
-substituted ara-C 
derivatives have been synthesized and characterized in the past. We demonstrated 
that N
4
-acyl-derivatives of ara-C were active in vivo as liposomal formulations at 
concentrations 2 - 4 times lower than ara-C.2 However, the protection of the N
4
-acyl-
ara-C derivatives against enzymatic deamination was only partially achieved and 
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suggested to be insufficient for a significant improvement of the cytotoxic properties. 
Based on these findings, we synthesized a new class of N
4
-alkyl-ara-C derivatives.3,4 
These compounds show a typical structure-activity correlation between the length of 
the alkyl side chain and their anti-tumor activity.3 The most effective derivative, N4-
octadecyl-ara-C (NOAC) is highly lipophilic and extremely resistant towards 
deamination.5 NOAC exerts excellent anti-tumor activity after oral and parenteral 
therapy.6-8 In a recent study the activity of NOAC against freshly explanted clonogenic 
cells from human tumors was determined and compared with conventional anti-tumor 
agents. NOAC was used in two liposomal preparations, a stable lyophilized and a 
freshly prepared liquid formulation. Both formulations inhibited tumor colony formation 
equally in a concentration-dependent fashion. At optimal conditions liposomal NOAC 
had a significantly better activity compared to the clinically used drugs cisplatin, 
doxorubicin, 5-fluorouracil, gemcitabine, mitomycin C and etoposide. Furthermore, in a 
hematopoietic stem cell assay NOAC was less toxic than ara-C and doxorubicin by 
factors ranging from 2.5 to 200, indicating that this drug is well tolerated at high doses.9 
In contrast to the parent drug ara-C, the cellular uptake of NOAC is nucleoside-
transporter independent and only insignificant amounts are phosphorylated to ara-C 
triphosphate (ara-CTP). Furthermore, NOAC is cytotoxic in ara-C resistant HL-60 
cells10,11 and treatment of multidrug resistant tumor cells did not induce P-170 
glycoprotein expression, suggesting that the N4-alkyl-ara-C derivatives are able to 
circumvent MDR1 multidrug resistance.12 We conclude therefore that the mechanisms 
of action of the N
4
-alkyl-ara-C derivatives are different from ara-C.  
 - 3 - 
Recently, we further modified NOAC by the synthesis of new duplex drugs that 
combine the clinically used drugs ara-C and 5-fluorodeoxyuridine (5-FdU) with NOAC 
yielding the heterodinucleoside phosphates arabinocytidylyl-N4-octadecyl-1-β-D-
arabinofuranosyl-cytosine (ara-C-NOAC) and 2’-deoxy-5-fluorouridylyl-N4-octadecyl-1-
β-D-arabinofurano-sylcytosine (5-FdU-NOAC). Depending on the synthesis conditions, 
the duplex drugs are linked either via 5’→5’ or 3’→5’ bridges. Due to the combination of 
the effects of both active molecules that can be released in the cells as monomers or 
as the corresponding monophosphates the cytotoxic activity of the duplex drugs is 
expected to be more effective as compared to the monomers. Further we anticipate 
that monophosphorylated ara-C (ara-CMP) and 5-FdU (5-FdU-MP), respectively, are 
directly formed in the cell after enzymatic cleavage of the duplex drugs. Thus, 
monophosphorylated molecules would not have to pass the first phosphorlyation step, 
which is known to be rate limiting. 
The chemical modification of ara-C and other nucleosides and their formulation in 
liposomes render these new cytotoxic drugs interesting candidates for further 
developments. 
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 Materials and Methods 
 
Chemicals 
 
Soy phosphatidylcholine (SPC) was obtained from L. Meyer, Hamburg, Germany. 
Cholesterol (Fluka AG, Buchs, Switzerland) was re-crystallized from methanol. 
Poly(ethylene glycol)-dipalmitoylphosphatidyl ethanolamine (PEG-DPPE, Mr 2750) was 
synthesized as described.13 DL-α-Tocopherol, all buffer salts and other chemicals 
used were of analytical grade and obtained from Merck, Darmstadt, Germany or Fluka.  
 
Synthesis of lipophilic arabinofuranosyl cytosine derivatives and 
heterodinucleoside phosphate duplex drugs 
 
NOAC and all other N4-alkyl derivatives of ara-C are synthesized by starting from 
uridine that is converted to an intermediary 1,2,4-triazolyl compound and reacted with 
octadecylamine. After cleavage of the O-acetyl protection groups on the arabinose, N4-
octadecyl-ara-C is obtained as crystalline solid at yields of 80-90%.3 The 
heterodinucleoside duplex drugs ara-C-NOAC and 5-FdU-NOAC are synthesized by 
condensation of NOAC via a 5’→5’ or 3’→5’ phosphodiester linkage to ara-C or 5-FdU, 
respectively, using the phosphotriester method as described.4,14 Figure 1 shows the 
chemical structures of NOAC and the lipophilic nucleoside duplex drugs. 
 - 5 - 
Liposome preparation 
A stable lyophilized liposome preparation of NOAC is prepared as follows. The lipids 
SPC (40 mg/ml), cholesterol (4 mg/ml), D,L-α-Tocopherol (0.2 mg/ml) and NOAC (5 
mg/ml) are dissolved in methanol/methylene chloride (1 : 1, v/v) in a round bottom 
flask. PEG-modified liposomes are obtained by addition of PEG(2000)-DPPE (14 
mg/ml) to the basic lipids. The organic solvent is removed on a rotatory evaporator 
(Büchi, Flawil, Switzerland) at 40°C during 30-60 min. The lipids and NOAC are 
solubilized by addition of an appropriate volume of phosphate buffer (10 mM, pH 7.4) 
containing 230 mM mannitol (Fluka, PB-mannitol) that serves as a cryoprotectant, 
followed by careful shaking of the flask until all lipids are suspended in the aqueous 
medium. Some glass beads can be added to facilitate the detachment of the lipids from 
the glass of the flask. Small unilamellar liposomes can be prepared either by high-
pressure filter extrusion or by detergent dialysis. In the case of dialysis the detergent 
sodium cholate (Merck, Darmstadt, Germany) is added initially to the organic lipid 
mixture at a molar ratio of 0.6 - 0.7 referred to all lipids and NOAC.2 Alternatively, the 
detergents octyl glucoside or octanoyl-N-methyl-glucamide (MEGA-8) can be used at a 
molar ratio of 0.2.15 After solubilization with PB-mannitol the lipid/drug/detergent mixed 
micelles are dialyzed against PB-mannitol using a LipoprepR instrument (Diachema, 
Munich, Germany). Larger volumes (50-500 ml) of liposomes are prepared using a 
capillary dialysis instrument.16 The resulting liposomes are sterile filtrated (0.2 µm, 
Gelman Sciences, Ann Arbor, MI), filled at appropriate volumes (e.g. 10 ml liposomes 
with 5 mg NOAC/ml) into sterile vials, frozen in liquid nitrogen and lyophilized during 
28-48 h (Dura-DryTM lyophilizer, FTS Systems, New York). 
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The amount of incorporated NOAC can be determined by addition of a trace amount of 
tritium-labeled NOAC (3H-NOAC, Amersham Int., Amersham, UK), followed by liquid 
scintillation counting. Alternatively, NOAC can be quantified by HPLC.17,18
The lyophilized liposomes are reconstituted shortly before use with sterile water or 
0.9% sodium chloride. Liposome size and homogeneity are monitored by laser light 
scattering (Submicron Particle Sizer Model 370, Nicomp, Sta. Barbara, CA, USA). 
Liposome formulations containing the duplex drugs ara-C-NOAC or 5-FdU-NOAC are 
prepared likewise.  
The concentration of NOAC and the duplex drugs ara-C-NOAC or 5-FdU-NOAC in the 
liposomes can be varied from 1 mg/ml to about 10 mg/ml, depending on the 
concentration of phospholipids, the lipid composition and the method of liposome 
preparation. Reconstituted lyophilized liposomes retain their size and homogeneity 
longer than 72 h after reconstitution. The drugs remain chemically stable during the 
freeze drying process and reconstitution. Liposome preparations are ready for 
parenteral use within 1-2 hours after reconstitution. 
 
 
Properties of NOAC and the duplex drugs 
 
The cytotoxic activity of the nucleoside drugs was tested in vitro on human tumor cell 
lines using a dye reduction assay.19,20 The IC50 values for NOAC and the duplex drugs 
are summarized in Table I. Furthermore, the anti-tumor activity of NOAC and the 
duplex drugs ara-C-NOAC and 5-FdU-NOAC were confirmed by the National Cancer 
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Institute (NCI) in vitro drug screening program where they were found to be active 
against several types of human tumors.21
In an experiment using the L1210 mouse leukemia model we compared the cytotoxic 
activity of NOAC formulated in plain and in PEG-liposomes of 80-160 nm mean 
diameter. As summarized in Table II, the antitumor activity of NOAC was excellent, 
irrespective of the liposome lipid composition. PEG-coating of the liposomes did not 
improve the anti-tumor effect in the L1210 leukemia. However, it is conceivable that 
NOAC incorporated in long circulating PEG-liposomes might have improved activity in 
solid tumors, despite of the transfer of the drug into plasma proteins (see below). 
The inhibition of tumor colony forming from freshly explanted human tumors treated 
with liposomal NOAC is shown in Figure 2 which summarizes the growth inhibitory 
activity of NOAC after short- and long-term exposure with increasing drug 
concentrations obtained with lyophilized and freshly prepared liposomes. The lipophilic 
ara-C derivative had a strong concentration dependent effect on colony formation on a 
panel of 50 tumor samples of various tumor types. A maximal inhibition of tumor growth 
was found in 28/50 (56%) samples with the short-term incubation (1 h) and in 39/50 
(78%) samples with the long-term incubations (21-28 days). At 100 µM and long-term 
exposure NOAC proved to be active against tumor cells that were resistant to cisplatin, 
doxorubicin, 5-fluorouracil, gemcitabine, mitomycin C and etoposide. There was no 
difference in NOAC activity between the application of lyophilized and freshly prepared 
liquid liposomes.9  
 
In an in vivo experiment a human acute lymphatic leukemia (ALL) xenotransplanted to 
NOD/SCID-3 mice was used to evaluate the anti-leukemic effect of NOAC in 
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comparison to standard agents. As summarized in Table III liposomal NOAC induced 
the prevention of leukemia development without causing severe side effects at lower 
doses. The prevention of peritoneal tumors and ascites in the ALL-SCID-3 model was 
achieved with 8-fold lower drug concentrations of liposomal NOAC as compared to ara-
C.22  
 
In several aspects, the lipophilic ara-C derivative NOAC was found to have different 
pharmacological effects as compared to ara-C. Total uptake after incubation of 
liposomal NOAC with tumor cells was generally 5-10-fold higher as ara-C. NOAC 
distributes to more than 90% into the membrane fraction of a cell extract, whereas ara-
C is distributed by more than 95% to the cytoplasmic fraction. Furthermore, the uptake 
mechanism of NOAC was shown to be independent of the nucleoside transport 
mechanism involved for ara-C and known to be sensitive to dipyridamole and 
deoxycytidine. NOAC uptake and cytotoxicity were not decreased in the presence of 
these blocking agents. NOAC is not a substrate for deoxycytidine kinase, the key 
enzyme of ara-C phosphorylation, suggesting other mechanisms of action.5,6,10  
NOAC has several advantages compared to other lipophilic ara-C derivatives such as 
ara-C ocfosfate (ara-CMP-stearyl ester, YNK-01)23 and thioether-linked lipid 
conjugates24 which are orally active prodrugs of ara-C. NOAC is both orally and 
parenterally active, whereas ara-C ocfosfate and and the thioether-linked lipid 
conjugates cannot be applied parenterally due to their hemolytic toxicity. Furthermore, 
NOAC is active against solid and drug resistant tumors, whereas cytarabine ocfosfate 
and BH-AC are classical prodrugs of ara-C with an activity spectrum that is not 
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significantly different from the parent drug. In an experimental phase I study with 
liposomal NOAC the plasma elimination half-life in cancer patients ranged between 11-
16 h with peak plasma levels of 180-240 µM at 600 mg NOAC/m2 without untoward 
toxic effects, warranting further clinical development of this new drug.25
 
The duplex drugs were found to be strong inhibitors of the cell cycle. They mainly arrest 
tumor cells in the early S-phase.19,20 With the duplex drugs cell uptake, intracellular 
distribution and fate and metabolism were not yet investigated. However, due to their 
similarity to NOAC it can be assumed that they have comparable properties. 5-FdU-
NOAC was found overcome 5-FdU resistance in p53 mutated and androgen-
independent DU-145 and PC-3 cells.20 It is likely that the heteronucleoside dimer is 
cleaved to 5-FdUMP and NOAC, resulting in sustained intracellular drug concentrations 
over an extended period, consequently increasing duration and magnitude of the 
cytotoxic effect. This hypothesis is supported by the fact that the duplex drug 
specifically inhibits TS activity (see Table I) and that it exerts a cell cycle phase-
dependent cytotoxicity, two mechanisms characteristic for 5-FdU. The higher 
concentrations and longer incubation periods that are required in vitro for the cytotoxic 
effect of 5-FdU-NOAC can possibly be explained by its prodrug nature, resulting in 
persisting intracellular concentrations of the active metabolites. The slow hydrolyis of 
the duplex drug by phosphodiesterase-I and human serum further indicate the prodrug 
nature of 5-FdU-NOAC. Thus, due to expected changes of the pharmacokinetic 
properties and the prodrug character of 5-FdU-NOAC the lipophilic duplex drug may 
have more favourable in vivo properties than the individual compounds 5-FdU and 
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NOAC. In previous studies performed with similar heterodinucleoside phosphate 
dimers composed of the antivirally active nucleosides azidothymidine (AZT) and 
dideoxycytidine (ddC) and formulated in liposomes we found significantly different 
pharmacokinetic properties and superior antiviral effects in comparison to the parent 
hydrophilic nucleosides in the murine Rauscher leukaemia virus model.26
 
Distribution of NOAC to blood cells and plasma proteins 
 
An important finding was that NOAC is not tightly anchored to the liposomal lipid bilayer 
and thus is readily distributed in the blood mainly into erythrocyte membranes and 
lipoproteins.27 It is known that unilamellar liposomes aggregate with LDL and allow the 
transfer of incorporated drugs from the liposomes to LDL. Similar to the observation of 
others for other lipophilic drugs,28  we found that after intravenous injection of liposomal 
NOAC the drug is transferred within short time from the liposome bilayers to 
erythrocyte membranes (30%), plasma proteins (<67%) and leukocytes (<2%).29
Thus, liposomes provide an ideal pharmaceutical formulation for NOAC to assure the 
transfer of the drug to lipoproteins, especially LDL. The natural affinity of NOAC for LDL 
provides an interesting rationale for the specific delivery of the drug to tumors. Growing 
and dividing cells require cholesterol for membrane synthesis that is delivered by LDL. 
This accounts also for cancer cells where an increased LDL uptake in tumors with high 
metastatic potential and aggressive or undifferentiated character is known. The LDL 
mediated uptake and cytotoxic effects of NOAC was also studied in vitro on Daudi 
lymphoma cells. NOAC was either incorporated into LDL or liposomes. Specific binding 
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of NOAC-LDL to Daudi cells was 5 times higher than to human lymphocytes. LDL 
receptor binding could be blocked and up- or down regulated. In a cytotoxicity test the 
IC50 of NOAC-LDL was about 160 µM. Blocking the LDL receptors with LDL protected 
50% of the cells from NOAC cytotoxicity. The natural affinity of NOAC for LDL provides 
an interesting rationale for the specific delivery of the drug to tumors that express 
elevated numbers of LDL receptors.30 
 
Conclusions and prospects 
 
With the chemical transformation of water-soluble nucleosides into lipophilic 
compounds and their incorporation into liposomes as their carriers we developed a new 
class of cytotoxic and antiviral drugs that can be applied for tumor treatment by 
parenteral routes. Lipophilic ara-C derivatives, particularly NOAC and the duplex drugs 
composed of NOAC and ara-C or 5-FdU represent very promising new anticancer 
drugs with high cytotoxic activity and strong apoptosis inducing capability. 
 
Based on our findings we conclude that owing to the chemical modification of ara-C 
and 5-FdU to molecules that show new physico-chemical properties such as high 
lipophilicity and stability against enzymatic degradation, together with the possibility to 
prepare lyophilized liposome formulations of these compounds, more potent drugs are 
made available. The mechanisms of action of the new drugs seem to be different from 
those of the parent water-soluble nucleosides, and as an important finding they seem 
to be able to overcome drug resistance mechanisms. The composition of the liposomes 
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seems not to represent a crucial factor in the pharmacological properites of the new 
derivatives. As shown with the L1210 leukemia model, the addition of PEG-lipids did 
not contribute to an enhancement of the cytotoxic effect (see Table II). This property 
can be explained with the in vivo distribution experiments and the in vitro incubation 
studies with plasma where we observed a fast transfer of NOAC from the liposome 
membranes to plasma proteins and erythrocytes.27,29 Thus, the liposomes serve mainly 
as a pharmaceutical formulation to permit solubilisation and parenteral administration of 
the new derivatives.  
 
In conclusion, the chemical modification of water-soluble molecules by attachment of 
long alkyl chains and their stable incorporation into the bilayer membranes of small 
unilamellar liposomes represent a very promising method for the development of new 
drugs not only for the treatment of tumors or infections, but also for many other 
diseases. 
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Legends to Figures and Tables 
 
Table I 
In vitro cytotoxicity (IC50) and inhibition of thymidylate synthase (TS) on DU-145 and 
PC-3 prostate tumor cells by the duplex drugs in comparison to 5-FdU, ara-C and 
NOAC 
 
Table II 
Cytostatic activity of NOAC in plain and in PEG-liposomes in the L1210 mouse 
leukemia model after intravenous therapy on days 2 and 6. 
 
Table III 
Antileukemic activity of liposomal NOAC in the ALL-SCID-3 leukemia model 
 
Figure 1 
Chemical structures of NOAC (N4-octadecyl-1-β-D-arabinofuranosyl cytosine) and the 
duplex drugs 5-FdU-NOAC (2’-deoxy-5-fluorouridylyl-N4-octadecyl-1-β-D-arabino-
furanosyl cytosine) and ara-C-NOAC (arabinocytidylyl-N4-octadecyl-1-β-D-
arabinofuranosyl cytosine).  
 
Figure 2 
Inhibition of tumor colony forming by NOAC from freshly explanted human tumors 
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Table I 
In vitro cytotoxicity and inhibition of thymidylate synthase 
 
Drug IC50 (µM) 
DU-145 
50% TS 
inhibition (µM) 
 
DU-145  
IC50 (µM) 
PC-3 
50% TS 
inhibition (µM) 
 
PC-3 
 
 
5-FdU 
 
3.4 
 
0.005 
 
3.4 
 
0.006 
5-FdU-(5’→5’)-NOAC 4.2 0.66 8.2 0.64 
Ara C 5.4 na 7.3 na 
Ara C-(5’→5’)-NOAC 12 na 123 na 
NOAC 134 na 110 na 
 
na, not applicable 
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Table II 
 
Cytostatic activity of NOAC in plain and in PEG-liposomes 
 
Preparationa Total dose 
µmol/kg 
Survival Time 
(days) 
  
Mean ±  S.D. 
T/Cb
% 
Survivors 
60 days 
 
NOAC in PEG 
liposomes 
 
100 
 
60 
 
857 
 
6/6 
 50 52 ± 18 750 5/6 
NOAC in plain 
liposomes 
100 60 857 6/6 
 50 52 ± 19 744 5/6 
Ara-C in PBc 200 20 ± 19 282 1/6 
 400 23 ± 20 297 1/5 
Controls -- 7 100 0/6 
 
a, On day 0, 105 L1210 cells were injected i.v. into BDF1 mice. I.v. treatment was on 
days 2 and 6. 
b, Increase of lifespan T/C% calculated including the 60 d survivors. S.D., standard 
deviation. 
c, PB, phosphate buffer (67 mM, pH 7.4) 
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Table III  
Antileukemic activity of liposomal NOAC 
 
Substancea Route Dose/inj. 
mg/kg   µmol/kg 
Peritoreal
Tumors 
Average tumor 
burden 
(ml or g/mouse)b
Experiment A: 
saline i.p. - 6/7 1.8 ± 1.16  
ara-C i.p. 100       411 0/8 0 
NOAC i.p. 100       200 0/8 0 
vincristine i.p. 1         1.2 0/7 0 
Experiment B: 
saline i.p. - 8/8 2.92 ± 1.69 
NOAC i.p. 50       100 0/8 0 
NOAC i.p. 25         50 0/8 0 
NOAC oral 100       200 0/8 0 
NOAC i.v. 25         50 0/3c 0 
 
 
a Leukemia cells (106/mouse) were inoculated i.p. on day zero (6-8 animals/group). 
Treatment started on day 1. Treatment schedule was on day 1, 4, 7, 11 after tumor 
inoculation. 
 
b Average tumor burden given as sum of peritoneal ascites fluid and solid tumor 
nodules in ml or gram per mouse. 
 
c 3 of 6 mice died due to toxicity.  
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Figure 1 
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 Figure 2  
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